Kristine Holgersen1, Peter Helding Kvist2, Helle Markholst3, Axel Kornerup Hansen4, Thomas Lindebo Holm5. 1. Novo Nordisk - LIFE In Vivo Pharmacology Centre, Frederiksberg, Denmark. Electronic address: KHLG@novonordisk.com. 2. Department of Histology, Novo Nordisk A/S, Maaloev, Denmark. Electronic address: PHKv@novonordisk.com. 3. Pharmacology, Novo Nordisk A/S, Maaloev, Denmark. Electronic address: HMar@novonordisk.com. 4. Department of Veterinary Disease Biology, Faculty of Health and Medical Sciences, University of Copenhagen, Frederiksberg, Denmark. Electronic address: akh@sund.ku.dk. 5. Department of Immunopharmacology, Novo Nordisk A/S, Maaloev, Denmark. Electronic address: ThLH@novonordisk.com.
Abstract
BACKGROUND: In inflammatory bowel disease a defective mucosal barrier, a dysregulated immune response and an excessive reactivity against the gut microbiota are assumed to cause a breakdown of the intestinal homeostasis and lead to chronic inflammation. Piroxicam treatment is a method for induction of colitis in IL-10 k.o. mice, which integrates a dysfunction of both the intestinal barrier and the immune system. However, the translational value of this model has not been thoroughly clarified. AIM: To characterise the piroxicam-accelerated colitis (PAC) IL-10 k.o. model with respect to clinical features, pathogenic mechanisms and its ability to respond to existing therapies. METHODS: The PAC IL-10k.o. model was established on a C57BL/6J background and the clinical manifestations, immunological mechanisms and efficacy of ampicillin and anti-IL-12/23p40 treatment were assessed. RESULTS: The PAC IL-10 k.o. mice developed weight loss and diarrhoea, and colonoscopy revealed a thickened granulomatous mucosa. Histological evaluation of ileum and colon showed Crohn's disease-like changes with pronounced hyperplasia and focal transmural inflammation. Ileitis was also observed in piroxicam treated wild type mice. The total number of neutrophils, monocytes and natural killer cells was elevated in the blood compared to IL-10 k.o. and wild type mice, indicating a role of the innate immune system in the pathogenesis. These findings were supported by analyses of the intestinal cytokine profile. Ampicillin and anti-IL-12/23p40 treatment significantly suppressed disease in the model. CONCLUSION: The PAC IL-10 k.o. model resembles several features of Crohn's disease and could be a useful in vivo model in preclinical research.
BACKGROUND: In inflammatory bowel disease a defective mucosal barrier, a dysregulated immune response and an excessive reactivity against the gut microbiota are assumed to cause a breakdown of the intestinal homeostasis and lead to chronic inflammation. Piroxicam treatment is a method for induction of colitis in IL-10 k.o. mice, which integrates a dysfunction of both the intestinal barrier and the immune system. However, the translational value of this model has not been thoroughly clarified. AIM: To characterise the piroxicam-accelerated colitis (PAC) IL-10 k.o. model with respect to clinical features, pathogenic mechanisms and its ability to respond to existing therapies. METHODS: The PAC IL-10k.o. model was established on a C57BL/6J background and the clinical manifestations, immunological mechanisms and efficacy of ampicillin and anti-IL-12/23p40 treatment were assessed. RESULTS: The PAC IL-10 k.o. mice developed weight loss and diarrhoea, and colonoscopy revealed a thickened granulomatous mucosa. Histological evaluation of ileum and colon showed Crohn's disease-like changes with pronounced hyperplasia and focal transmural inflammation. Ileitis was also observed in piroxicam treated wild type mice. The total number of neutrophils, monocytes and natural killer cells was elevated in the blood compared to IL-10 k.o. and wild type mice, indicating a role of the innate immune system in the pathogenesis. These findings were supported by analyses of the intestinal cytokine profile. Ampicillin and anti-IL-12/23p40 treatment significantly suppressed disease in the model. CONCLUSION: The PAC IL-10 k.o. model resembles several features of Crohn's disease and could be a useful in vivo model in preclinical research.
Authors: Bill Vestergaard; Łukasz Krych; Leif R Lund; Bettina P Jørgensen; Lars Hansen; Henrik E Jensen; Dennis S Nielsen; Axel K Hansen Journal: Comp Med Date: 2015-10 Impact factor: 0.982
Authors: Jakob Benedict Seidelin; Mehmet Coskun; Peter Helding Kvist; Thomas Lindebo Holm; Kristine Holgersen; Ole Haagen Nielsen Journal: J Gastroenterol Date: 2014-08-12 Impact factor: 7.527
Authors: Brigid S Boland; Zhaoren He; Matthew S Tsai; Jocelyn G Olvera; Kyla D Omilusik; Han G Duong; Eleanor S Kim; Abigail E Limary; Wenhao Jin; J Justin Milner; Bingfei Yu; Shefali A Patel; Tiani L Louis; Tiffani Tysl; Nadia S Kurd; Alexandra Bortnick; Lauren K Quezada; Jad N Kanbar; Ara Miralles; Danny Huylebroeck; Mark A Valasek; Parambir S Dulai; Siddharth Singh; Li-Fan Lu; Jack D Bui; Cornelis Murre; William J Sandborn; Ananda W Goldrath; Gene W Yeo; John T Chang Journal: Sci Immunol Date: 2020-08-21
Authors: David Meriwether; Dawoud Sulaiman; Carmen Volpe; Anna Dorfman; Victor Grijalva; Nasrin Dorreh; R Sergio Solorzano-Vargas; Jifang Wang; Ellen O'Connor; Jeremy Papesh; Muriel Larauche; Hannah Trost; Mayakonda N Palgunachari; G M Anantharamaiah; Harvey R Herschman; Martin G Martin; Alan M Fogelman; Srinivasa T Reddy Journal: J Clin Invest Date: 2019-06-11 Impact factor: 19.456
Authors: Jesus Cosin-Roger; Simona Simmen; Hassan Melhem; Kirstin Atrott; Isabelle Frey-Wagner; Martin Hausmann; Cheryl de Vallière; Marianne R Spalinger; Patrick Spielmann; Roland H Wenger; Jonas Zeitz; Stephan R Vavricka; Gerhard Rogler; Pedro A Ruiz Journal: Nat Commun Date: 2017-07-24 Impact factor: 14.919
Authors: Christoffer Soendergaard; Peter Helding Kvist; Peter Thygesen; Mats Reslow; Ole Haagen Nielsen; John Joseph Kopchick; Thomas Lindebo Holm Journal: Int J Mol Sci Date: 2017-09-23 Impact factor: 5.923